NOVATO, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Mount Tam Biotechnologies, Inc. ("Mount Tam") (OTC PINK:MNTM) is pleased to announce that Dr. Bryan F. Cox has been appointed as a scientific advisor to Mount Tam Biotechnologies for the development of novel rapamycin analogs to address serious unmet need across a range of autoimmune and rare diseases.
According to Dr. Richard Marshak, Mount Tam CEO, “Bryan brings a tremendous range of experience that is a critical complement to our core capabilities. His addition to Mount Tam as scientific advisor helps to assure that we have the world-class team necessary for optimizing drug candidates and carrying them forward to successful IND filings, and into Phase 1 clinical trials.”
Dr. Cox is currently President of CoPharm Global Consulting, a boutique consultancy focused on providing guidance for biotechs and due diligence teams as they determine the best path forward from early discovery to first-in-man studies. Prior to CoPharm Global, he was Director of Integrative Pharmacology at Abbott - responsible for both lead optimization and IND-enabling studies. He served on both the Discovery and Preclinical Safety Leadership Teams. He has (co-) authored/approved over 250 documents for Regulatory submission and participated in the advancement of over 60 compounds to Phase I clinical trials. Prior to joining Abbott, Dr. Cox was with Rhone Poulenc Rorer. Dr. Cox has published more than 100 papers in peer-reviewed journals and has twice been elected to Council for the American Society of Pharmacology and Experimental Therapeutics. He received his PhD in pharmacology from the University of Iowa and is currently an adjunct Professor of Pharmacology at the University of Iowa, College of Medicine.
“I am very excited to work with Mount Tam in advancing these novel rapamycin analogs to IND and Phase I clinical trials. As the science around mTORC1 and mTORC2 is rapidly evolving, the Mount Tam platform offers a unique opportunity to address multiple disease states where patients previously had few pharmacologic options,” says Dr. Cox.
About Mount Tam Biotechnologies, Inc.
Mount Tam Biotechnologies, Inc. was established to develop, optimize and bring to market leading medical compounds to better the health and well being of millions of people who have been affected by autoimmune diseases. The organization's most advanced product focuses on the treatment of systemic lupus erythematosus (SLE).
Mount Tam has partnered with the world-renowned Buck Institute for Research on Aging through a worldwide exclusive licensing and collaboration agreement. The assets, which are focused on autoimmune diseases, are highly target-specific polyketides--a class of compounds with an extremely successful track record with the FDA drug approval process. The assets are supported by intellectual property consisting of over 45 worldwide issued patents and patent applications, including composition of matter, manufacturing and therapeutic area applications.
Mount Tam intends to apply its first and most advanced asset, TAM-01, to the Investigational New Drug (IND) application phase of the FDA. It has already completed non-GLP pre-clinical development. The primary focus is to develop TAM-01 for the treatment of systemic lupus erythematosus (SLE). Mount Tam will use the R&D conducted on TAM-01 as the core science for additional assets, including its second product known as TAM-02, which is currently focused on multiple sclerosis (MS).
For more information visit www.MountTamBiotech.com
The information disclosed in this press release is made as of the date hereof and reflects Mount Tam’s most current assessment of its historical position and financial performance. Actual results may differ from those contained herein due factors outside of the control of Mount Tam. Additionally, this press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections.
These forward-looking statements are not guarantees of future performance and are subject to uncertainties and other factors that could cause actual results to differ materially from those expressed in the forward-looking statements including, without limitation, the risks, uncertainties, including the uncertainties surrounding the current market volatility, and other factors Mount Tam identifies from time to time in its filings with the SEC. Forward-looking statements are identified by wording such as "scheduled (future sense)" "intend(s)", "plan(s)" "expect(s)", "believe(s)" "will" "estimate(s)", "anticipate(s)", "expect(s)", "may", "would", "could" or "should" or, in each case, the negative thereof, other variations thereon, or comparable terminology that implies anticipated future performance, timing of an IND application, or the results of any such application. Although Mount Tam believes that the assumptions on which these forward-looking statements are based are reasonable, any of those assumptions could prove to be inaccurate and, as a result, the forward-looking statements based on those assumptions also could be incorrect. You should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this release are made as of the date hereof, and Mount Tam disclaims any intention or obligation to update the forward-looking statements for subsequent events.
Company Contact: Jim Stapleton Chief Financial Officer firstname.lastname@example.org Phone: 425-214-4079
Source:Mount Tam Biotechnologies, Inc.